**Supplementary Figure 1. (A)** The densitometry of the circ-ZDHHC5 in tissues. **(B)** The fluorescence intensityof ZEB1 protein in the treated ESCC cells. **(C)**RIP Assay was performed to detect the enrichment of circ-ZDHHC5 using Ago2 or IgG antibody. (*\*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001, \*\*\*\*p < 0.0001*)



**Supplementary Tables. Clinical characteristics of patients’ samples.**

S Table 1. Clinical characteristics in 24 ESCC patients (tissues)

|  |  |
| --- | --- |
| **characteristic** | **case** |
|
| Age(yeas) |  |
| <65 | 14 |
| ≥65 | 10 |
| Gender |  |
| Female | 7 |
| Male | 17 |
| Tumor size(cm) |  |
| <5 | 11 |
| ≥5 | 13 |
| Histological grade |  |
| High | 9 |
| Middle-low | 15 |
| Lymph node metastasis |  |
| Negative | 4 |
| Positive | 20 |
| TNM stage |  |
| I–II | 8 |
| III–IV | 16 |

S Table 2. Clinical characteristics in 20 ESCC patients (plasmas)

|  |  |
| --- | --- |
| **characteristic** | **case** |
|
| Age(yeas) |  |
| <65 | 7 |
| ≥65 | 13 |
| Gender |  |
| Female | 5 |
| Male | 15 |
| Tumor size(cm) |  |
| <5 | 6 |
| ≥5 | 14 |
| Histological grade |  |
| High | 8 |
| Middle-low | 12 |
| Lymph node metastasis |  |
| Negative | 5 |
| Positive | 15 |
| TNM stage |  |
| I–II | 8 |
| III–IV | 12 |